scholarly article | Q13442814 |
P50 | author | Dorry Segev | Q23881945 |
P2093 | author name string | A L Singer | |
R A Montgomery | |||
A A Zachary | |||
J E Locke | |||
B E Lonze | |||
C E Simpkins | |||
N N Dagher | |||
P2860 | cites work | Radiologic placement of tunneled hemodialysis catheters in occluded neck, chest, or small thyrocervical collateral veins in central venous occlusion | Q31846137 |
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | patient | Q181600 |
P304 | page(s) | 2154-2160 | |
P577 | publication date | 2010-07-15 | |
P1433 | published in | American Journal of Transplantation | Q4744273 |
P1476 | title | Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access | |
P478 | volume | 10 |
Q37990988 | Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale |
Q38206175 | Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options |
Q38392458 | Antibody-mediated rejection in pediatric kidney transplantation: pathophysiology, diagnosis, and management |
Q38126085 | B-cell regulation and its application to transplantation |
Q45178704 | Case Report: Successful Living Donor Kidney Transplantation in a Highly Human Leukocyte Antigen-Sensitized Recipient With a Positive Cytotoxic Crossmatch Using Bortezomib-Based Desensitization Without Intravenous Immunoglobulin |
Q38609238 | Complement inhibition as potential new therapy for antibody-mediated rejection. |
Q35567841 | Complement involvement in kidney diseases: From physiopathology to therapeutical targeting |
Q58120548 | Complement-mediated renal diseases after kidney transplantation - current diagnostic and therapeutic options in and recurrent diseases |
Q26829789 | Current state of renal transplant immunosuppression: Present and future |
Q47440056 | De novo thrombotic microangiopathy after kidney transplantation |
Q51278476 | Dosing Eculizumab for Antibody-Mediated Rejection in Kidney Transplantation: A Case Report. |
Q38914719 | Eculizumab for the Treatment of Severe Antibody-Mediated Rejection: A Case Report and Review of the Literature. |
Q33395870 | Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report |
Q33396637 | Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation |
Q52888455 | Effect of Treatment With Tabalumab, a B Cell-Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation. |
Q55409568 | Evaluating the Use of Bortezomib and Eculizumab in Desensitization of Transplant Patients. |
Q38144106 | Impact of donor-specific antibodies in reconstructive transplantation |
Q38006827 | Innovative strategies in living donor kidney transplantation |
Q37446883 | New immunosuppressive agents in pediatric transplantation |
Q48272177 | Nontraditional sites for vascular anastomoses to enable kidney transplantation in patients with major systemic venous thromboses |
Q38176005 | Novel immunosuppressive agents in kidney transplantation |
Q39968188 | Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field |
Q24599629 | Paroxysmal nocturnal hemoglobinuria from bench to bedside |
Q45736192 | Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody |
Q37888770 | Targeting B cells and antibody in transplantation |
Q47443910 | The lack of Lazarus effect with proteasome inhibition |
Q33406570 | The use of eculizumab in renal transplantation |
Q58754943 | Thrombotic microangiopathy after renal transplantation: Current insights in and recurrent disease |
Q37952349 | Transplant accommodation--are the lessons learned from xenotransplantation pertinent for clinical allotransplantation? |
Q27021397 | Treatment options and strategies for antibody mediated rejection after renal transplantation |
Q35790601 | Utility of HLA Antibody Testing in Kidney Transplantation |
Search more.